UNIVO is a vertically-integrated medical cannabis company including cultivation, manufacturing and distribution as well as the creation of innovative products and dosage forms for next-generation medical cannabis products.
UNIVO holds initial licenses for the entire supply chain:
To help patients worldwide with all natural Cannabis based solutions that treat a wide variety of indications with superior efficacy, improved safety and fewer side effects compared to currently available treatment.
To become a multinational Medical Cannabis Technology company that develops, grows, manufactures and distributes Medical Cannabis products worldwide using our industry leading technologies, expertise and supply chain.
The UNIVO Advantage
UNIVO will be offering a one-stop-shop medical cannabis solutions from seed to market.
Production will take place in our IMC-GMP approved facility and meets the regulatory guidelines of the Israeli Ministry of Health. All UNIVO products undergo rigorous laboratory testing to ensure both quality and regulatory compliance before leaving the factory for distribution to our customers and use by patients.
The production facility is equipped with cutting edge Ethanol and CO2 extraction technologies. The different properties of each extracting material enable optimal extraction of various substances from the plant in addition to the active ingredients CBD, THC. This “Entourage Effect” enhances the effect of the active ingredients.
Our specially developed proprietary Ethanol extraction technology low temperatures enabling us to extract pure oil without losing any terpenes and without the present of waxes and chlorophyll like no other competing products.
What makes UNIVO special
Factory & Laboratory
Havat Amit LTD
UNIVO has acquired 74% in the Amit Farm, a family business with decades of successful agricultural experience located in Southern Israel. The farm spans over 75,000m² of which 15,000 m² will be designated for cannabis growth. Amit Farm is authorized to build a cannabis growth farm for medical purposes under IMC-GAP regulations.
The farm will enable us to cultivate and breed unique cannabis strains which are targeted to meet specific medical needs. A portion of the farm will be allocated for use by start-up companies who are attempting to develop their own strains but lack the agricultural capabilities, resources and or expertise.
Estimated time for finalizing construction is Dec 2019, planting will start on Jan 2020.